Neurocrine Biosciences’ Vykat XR has been linked to seven deaths and nearly 100 hospitalizations since its approval 18 months ago for Prader-Willi syndrome. Regulatory reports do not prove causation and involve complex cases, but some experts say the evidence indicates unacceptable harm.